Page 4 - புதியது மருந்து சமர்ப்பிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Federal Court upholds validity of one pneumococcal vaccine patent, but holds two other patents invalid | Smart & Biggar

Federal Court upholds validity of one pneumococcal vaccine patent, but holds two other patents invalid | Smart & Biggar
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.

Merckv wyethWhile the courtFederal courtCanadian patentNew drug submissionபோது தி நீதிமன்றம்கூட்டாட்சியின் நீதிமன்றம்கனடியன் காப்புரிமைபுதியது மருந்து சமர்ப்பிப்பு

Acerus Reports First Quarter 2021 Financial Results

Acerus Reports First Quarter 2021 Financial Results Nachrichtenquelle: globenewswire | 13.05.2021, 13:30 | 54 | 0 TORONTO, May 13, 2021 (GLOBE NEWSWIRE) Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2021. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Q1 - 2021 Highlights Re-purchased all remaining NATESTO rights from Aytu Biopharma, allowing Acerus to build and leverage its commercial business across North America Expanded NATESTO access to 20 countries across Europe, Central Asia and the Middle East through an agreement with Maylen Farma (“Maylen”), a firm

United statesUnited arab emiratesSaudi arabiaKingdom of saudi arabiaAytu biopharmaChris wittyEd gudaitisAytu bioscienceMaylen farmaHealth canada approval statusAmneal pharmaceuticalsAcerus pharmaceuticals corporationCompany contactFirst generation capital incHealth canadaNorth america

Writing Multiple Marketing Applications Simultaneously With Accelerated Timelines

Writing Multiple Marketing Applications Simultaneously With Accelerated Timelines A mid-size pharmaceutical company and its development partner, a small biotechnology company engaged Veristat to complete the medical writing for their product’s Marketing Authorization Application (MAA), New Drug Application (NDA), and New Drug Submission (NDS). Learn how our medical writing team worked closely with the sponsors to write these marketing applications in an accelerated timeline since the product received Orphan Drug Designation in the United States and Europe and Priority Review status in Canada. Signing up provides unlimited access to: Trend and Leadership Articles Not yet a member of Clinical Leader? Register today.

United statesMarketing authorization applicationNew drug applicationNew drug submissionOrphan drug designationPriority reviewஒன்றுபட்டது மாநிலங்களில்சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம்புதியது மருந்து விண்ணப்பம்புதியது மருந்து சமர்ப்பிப்புஆர்ஃபந் மருந்து பதவிப்ரையாரிடீ விமர்சனம்

MorphoSys AG Reports First Quarter 2021 Results

MorphoSys AG Reports First Quarter 2021 Results Tremfya royalties of € 11.6 million Reaffirming group revenue guidance of € 150 to € 200 million Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST (1:00pm BST/8:00am EDT) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 5, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) reports financial results for the first quarter of 2021. For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline, said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. While we experienced headwinds from the pandemic in the first quarter, we are cautiously optimistic that the COVID-19 impact in the U.S. will start to diminish in the second half of 2021. We are confident in the potential of Monjuvi given its broad second-line label and overall profile in the r/r DLBCL setting. We are also making

United statesUnited kingdomThomas biegiJulia neugebauerJean paul kressMyles cloustonJeanette bressiJanssen biotech incXencor incDrug administrationJanssen research developmentMorphosys us incGroup revenuesExchange commissionUs communicationsMorphosys group key figures

Amylyx Pharmaceuticals Appoints Chris Aiello to Head of Canada and General Manager

Amylyx Pharmaceuticals Appoints Chris Aiello to Head of Canada and General Manager
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United kingdomJustin kleeMargaret olingerChris aielloSanofi genzymeJoshua cohenAmylyx pharmaceuticalsAmylyx pharmaceuticals incHealth canadaNew drug submissionSanofi genzyme canadaBusiness unit directorRare diseaseRare blood disordersGeneral managerChief commercial officer